Based on the Incyte Corporation stock forecast from 15 analysts, the average analyst target price for Incyte Corporation is USD 72.59 over the next 12 months. Incyte Corporation’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Incyte Corporation is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Incyte Corporation’s stock price was USD 68.84. Incyte Corporation’s stock price has changed by +0.42% over the past week, -3.11% over the past month and +13.30% over the last year.
No recent analyst target price found for Incyte Corporation
No recent average analyst rating found for Incyte Corporation
Company Overview Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation Read Less
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for tre...Read More
Frequently Asked Questions About Incyte Corporation (INCY) Stock
Based on ratings from 15 analysts Incyte Corporation's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, 1 sell and 17 hold ratings.
Unfortunately we do not have enough data on INCY's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for INCY is USD 72.59 over the next 12 months. The maximum analyst target price is USD 92 while the minimum anlayst target price is USD 48.
INCY stock's Price/Earning ratio is 761.67.
Our analysis grades INCY stock's Price / Earning ratio at F. This means that INCY stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this INCY may be a overvalued for its sector.
The last closing price of INCY's stock was USD 68.84.
The most recent market capitalization for INCY is USD 13.52B.
Based on targets from 15 analysts, the average taret price for INCY is projected at USD 72.59 over the next 12 months.
This means that INCY's stock price may go up by +5.45% over the next 12 months.
We can't find any ETFs which contains Incyte Corporation's stock.
As per our most recent records Incyte Corporation has 2,524 Employees.
Incyte Corporation's registered address is 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803.
You can get more information about it from Incyte Corporation's website at https://www.incyte.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Incyte Corporation (INCY) Stock
Based on ratings from 15 analysts Incyte Corporation's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, 1 sell and 17 hold ratings.
Unfortunately we do not have enough data on INCY's stock to indicate if its a good dividend stock.
Based on targets from 15 analysts, the average taret price for INCY is USD 72.59 over the next 12 months. The maximum analyst target price is USD 92 while the minimum anlayst target price is USD 48.
INCY stock's Price/Earning ratio is 761.67.
Our analysis grades INCY stock's Price / Earning ratio at F. This means that INCY stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this INCY may be a overvalued for its sector.
The last closing price of INCY's stock was USD 68.84.
The most recent market capitalization for INCY is USD 13.52B.
Based on targets from 15 analysts, the average taret price for INCY is projected at USD 72.59 over the next 12 months.
This means that INCY's stock price may go up by +5.45% over the next 12 months.
We can't find any ETFs which contains Incyte Corporation's stock.
As per our most recent records Incyte Corporation has 2,524 Employees.
Incyte Corporation's registered address is 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803.
You can get more information about it from Incyte Corporation's website at https://www.incyte.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INCY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
